Pharmadrug Inc.

C$0.01As of Sun 8 Nov 2026, 12:00 UTC

CSE:PHRXHealthcare

Country Canada

PE (Fwd) •••

TSR 8Y CAGR (52.73%)

Div yield —

ROE —

Drug Manufacturers (Specialty & Generic)

Beta (5Y) 0.65

PE TTM —

TSR TTM (75.00%)

Mkt cap C$0.671M

ROIC (238.09%)

SE Grade™

Value

Quality

Moat

Consensus

Reference

$0.0059

17.76%

237.39%

Hold 9|5|1|4|9

TTM

FYE 31 Dec CAD

FY2016

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026E

Trend

5Y

10Y

Peers

0.062

Revenue$M

0.063

0.068

0.072

0.077

0.082

0.087

0.095

0.101

0.107

0.115

0.067

7.01%

6.74%

72

5.53

Revenue growth%

0.40

0.45

0.40

0.40

2.54

1.30

3.38

4.03

6.03

8.13

7.04

4.03

1.92

71

26.34

Gross margin%

12.85

13.21

14.51

15.34

16.66

19.51

19.94

20.69

21.19

22.84

7.65

20.69

18.09

54

23.71

Operating margin%

12.44

12.34

13.79

14.06

13.16

11.90

9.10

8.57

6.68

8.06

7.67

8.57

12.12

67

15.22

Net margin%

22.15

20.91

22.63

25.58

27.44

28.95

29.50

30.72

29.87

28.55

13.88

29.50

28.00

50

25.82

P/E ratio (avg)x

32.08

34.16

37.86

40.49

43.71

49.19

53.93

59.19

67.45

71.50

12.92

59.19

46.45

10

22.04

EV/EBITx

23.86

28.92

31.66

35.43

34.72

41.80

46.93

51.73

59.78

63.98

16.80

51.73

38.61

67

17.80

FCF yield (avg)%

7.36

6.83

8.96

8.47

10.28

10.74

12.43

11.58

10.70

11.54

14.35

11.54

10.49

44

27.46

FCF margin%

21.29

23.69

24.67

26.68

29.28

31.63

29.72

31.49

32.23

30.88

14.91

31.49

29.50

61

0.720

FCF / Net incomex

1.502

1.534

1.665

1.721

1.955

2.034

2.442

2.735

3.125

3.035

0.652

2.735

1.995

30

6.20

ROIC%

21.30

21.39

21.36

19.93

20.42

18.41

16.68

13.93

16.48

14.59

7.47

16.48

19.17

16

17.83

Return on equity%

28.79

29.70

31.45

33.57

33.56

34.12

34.41

34.69

34.04

33.74

14.78

34.12

33.65

11

13.93

Return on assets%

6.60

8.76

7.99

9.88

7.36

9.06

7.66

8.55

6.75

4.78

19.07

7.66

7.83

41

—

EPS$

—

—

—

—

—

—

—

—

—

—

—

8.20%

9.10%

—

22.65

EPS growth%

25.32

25.74

27.05

26.41

29.08

26.90

24.74

21.81

20.66

19.76

12.94

21.81

25.53

50

—

Bookvalue per sh$

—

—

—

—

—

—

—

—

—

—

—

0.27%

(0.99%)

—

—

FCF per share$

—

—

—

—

—

—

—

—

—

—

—

(2.65%)

(3.51%)

—

—

Dividend per sh$

—

—

—

—

—

—

—

—

—

—

—

(2.45%)

(6.09%)

—

23.71

Div yield (avg)%

18.91

19.74

20.48

22.39

23.90

22.05

21.61

20.79

22.50

20.45

27.32

21.61

21.20

15

21.58

Payout ratio%

19.27

20.35

17.40

16.52

18.51

17.07

19.27

18.55

21.10

19.85

10.68

19.27

18.91

73

135.9

Shares (diluted)M

261.1

277.6

286.3

305.2

358.9

426.8

478.5

548.9

540.5

599.4

136.4

10.80%

9.77%

89

7.30

Buyback yield%

2.31

1.09

3.69

5.32

6.66

7.72

6.83

4.70

2.04

0.40

13.21

4.70

4.20

91

1.604

D/E ratiox

2.086

2.130

2.416

2.802

3.247

3.548

4.029

4.113

4.595

4.893

0.937

4.113

3.397

55

0.113

Enterprise value$M

—

—

—

—

—

—

—

—

—

—

0.032

(3.09%)

(3.47%)

57

0.069

LT debt$M

0.010

0.011

0.012

0.012

0.012

0.012

0.013

0.014

0.015

0.018

0.017

8.65%

5.83%

60

Peers (US$0.475M)

Cap (US$)

PE

KMT Hansa Corp.

0.527M

—

Vibe Growth Corporation

0.481M

—

Aequus Pharmaceuticals…

0.469M

—

Sunshine Biopharma…

0.525M

—

Capital

TTM

5Y

10Y

Leveragex

1.427

0.441

0.423

EBIT/Intx

0.144

0.063

0.058

Own earn%

34.52

(0.71)

3.95

Sh yield%

31.01

25.49

25.02

Owners

Insiders/Inst%

8.37

65.59

Short interest%

1.08

SBC / revenue%

0.31

Record

10Y

Profitable years

10/10

Revenue growth years

10/10

EPS growth years

10/10

Dividend streakyrs

15

Op margin range%

7–14

$1 testx

0.0

Incr. ROIC%

1

Growth vs revenue

Latest

Trend

10Y CAGR

Rel growth

Revenue

$0.115M

6.74%

1.00×

Cost of revenue

$0.078M

6.75%

1.00×

Operating expenses

$0.019M

6.65%

0.99×